A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406.
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Genmab; GlaxoSmithKline
- 14 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
- 04 Apr 2013 New trial record